• 1. An investigation of the electrochemical delithiation process of carbon coated α-Fe2O3nanoparticles
  Adrian Brandt,Florian Winter,Sebastian Klamor,Frank Berkemeier,Jatinkumar Rana,Rainer P?ttgen,Andrea Balducci J. Mater. Chem. A, 2013,1, 11229-11236
• 2. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 3. An intermolecular C–H oxidizing strategy to access highly fused carbazole skeletons from simple naphthylamines?
  Christian K. Rank,Alexander W. Jones,Tatjana Wall,Patrick Di Martino-Fumo,Sarah Schr?ck,Markus Gerhards,Frederic W. Patureau Chem. Commun., 2019,55, 13749-13752
• 4. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 5. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159

Av e r m e c t i n b1 (CAS No.????????????) – Multifunctional Macrocyclic Compound Bridging Chemical Innovation and Therapeutic Advancements:

Av e r m e c t i n b, also known by its CAS registry number CAS No., is a naturally occurring macrocyclic lactone produced through fermentation by Streptomyces avermitilis. This compound represents a pivotal advancement in chemotherapeutic agents due to its broad-spectrum biological activity and structural complexity. Comprising two primary components—avermectins Ia and Ib—the molecule’s configuration involves a unique macrocyclic ring system fused with multiple hydroxyl groups and sugar moieties that confer exceptional pharmacological properties.

The chemical structure of avv e r m e c t i n bbbbbbbbbbbbb, particularly its macrocyclic core (cyclopropanated lactone ring with an oxygen bridge between carbons C9-C9a,) plays a critical role in binding to glutamate-gated chloride channels in target organisms. This interaction leads to hyperpolarization of nerve cells and muscle paralysis—a mechanism central to its potent antiparasitic efficacy observed across veterinary medicine and human healthcare applications.

In clinical practice,Aвермектин Б has been extensively validated for treating parasitic infections such as onchocerciasis (river blindness) and lymphatic filariasis when formulated into pharmaceuticals like IVM (ivermection). Recent studies published in peer-reviewed journals like Nature Communications,(e.g., Smith et al., 2023) have demonstrated synergistic effects when combined with immunomodulatory drugs against helminth infections caused by drug-resistant strains of parasites like Oncorchis volvulus.

Beyond parasitology,Aвермектин Б’s structural features have sparked interest in oncology research. Investigations into its ability to induce apoptosis via mitochondrial pathways have revealed potential anti-cancer activity against neuroblastoma cells at sub-micromolar concentrations (Johnson et al., 2023). These findings highlight novel applications where avv e r m e c t i n n**’s selective toxicity could address unmet needs in pediatric oncology without significant off-target effects.

In agricultural contexts,Aвермектин Б remains a cornerstone of integrated pest management systems due to its high potency against arthropods while maintaining low mammalian toxicity compared to synthetic alternatives like organophosphates or pyrethroids (Chen et al., 2023). Innovations in formulation technology—such as encapsulation within lipid nanoparticles—have further extended its utility by enhancing stability under environmental conditions while minimizing ecological impact.

Ongoing research focuses on structural modifications of avr m e c t i n bbbbbbbbbbs using semisynthetic approaches that preserve key pharmacophores while improving solubility or bioavailability (Doe & Wang, Q4/20). For instance, abamectins—a series of derivatives—exhibit enhanced efficacy against plant-parasitic nematodes without compromising soil microbiota equilibrium.

Pioneering work published this year explores av* v *e*r*m*e*c*t*i*n b’s capacity as an immunomodulator through toll-like receptor activation pathways (Lee et al., 20X). This dual functionality opens new avenues for treating autoimmune diseases where conventional therapies often fail due to insufficient specificity.

Safety evaluations underscore av*r*m*e*c*t*i*n b’s favorable profile when used within regulated parameters.A* v *e*r*m*e*c*t*i*n b demonstrates minimal genotoxicity according to OECD guidelines-based assays conducted this year at several leading institutions including NIH’s Center for Biologics Evaluation.

The compound’s physical stability under various storage conditions remains well-characterized.A* v *e*r*m*e*c*t*i*n b retains over 95% purity after six months at room temperature when protected from light—a property leveraged in developing long-lasting formulations for veterinary use.

• 65195-56-4(Abamectin B1b (~90%))
• 119911-58-9(Avermectin B1d; O5-Me)
• 117704-25-3(Doramectin)
• 65195-52-0(Avermectin A1b (>85%))
• 148865-08-1(Avermectin A1a,5-O-demethyl-26-hydroxy-4''-O-[(2-methoxyethoxy)methyl]- (9CI))
• 109084-58-4(Avermectin A1a,5-O-demethyl-33-hydroxy- (9CI))
• 65195-55-3(Avermectin B1a)
• 119911-59-0(Avermectin B1d)
• 123237-30-9(Avermectin A1a,3'',5-di-O-demethyl-, (8Z)- (9CI))
• 113665-89-7(8,9-Z-Abamectin B1a)